Boston Scientific Acquires Atritech

Xconomy Boston — 

Natick, MA-based medical devices maker Boston Scientific has expanded its cardiovascular products business with the purchase of Atritech, a Plymouth, MN, developer of a device alternative to treating patients with atrial fibrillation who are at risk of stroke, the company says today. Boston Scientific (NYSE:BSX) is paying $100 million upfront for Atritech as up to $275 million in regulatory and commercial milestone fees through 2015, according to Boston Scientific. Atritech’s device is cleared for sale in Europe and but is still in development for the U.S. market.